Letter | Published:

Some Pharmacological Properties of a New Adrenergic β-Receptor Antagonist

Nature volume 212, pages 8890 (01 October 1966) | Download Citation

Subjects

Abstract

SEVERAL compounds have now been described as adrenergic β-receptor antagonists including dichloroisoprenaline1 pronethalol (‘Alderlin’)2, propranolol (‘Inderal’)3, MJ 1999 (ref. 4), and INPEA5. Propranolol is about ten times more active than the other compounds in blocking the inotropic and chronotropic actions of catecholamines6. Studies with pronethalol and propranolol have shown that adrenergic β-receptor antagonists are valuable in the treatment of various clinical disorders7–11. The use of pronethalol was restricted when it was shown to be a potential carcinogenic agent in mice12; propranolol is devoid of this action13. This communication describes some of the pharmacological properties of a new adrenergic β-receptor antagonist 1-isopropylamino-3-(3-tolyloxy)-2-propanol hydrochloride (‘I.C.I. 45,763’), selected from a series of phenoxypropanolamines synthesized by Crowther Smith and Wood14.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , and , J. Pharmacol., 122, 480 (1958).

  2. 2.

    , and , Lancet, ii, 311 (1962).

  3. 3.

    , , , , and , Lancet, i, 1080 (1964).

  4. 4.

    , , and , J. Pharmacol., 149, 161 (1965).

  5. 5.

    , , , and , J. Pharm. Pharmacol., 15, 26 (1963).

  6. 6.

    , Biochem. Pharmacol. (in the press).

  7. 7.

    , and , Brit. Med. J., ii, 1230 (1963).

  8. 8.

    , , and , Brit. Med. J., i, 891 (1965).

  9. 9.

    , , , and , Brit. Med. J., ii, 720 (1964).

  10. 10.

    , and , Brit. Med. J., ii, 337 (1965).

  11. 11.

    , , , , , and , Ciba Found. Symp., Cardiomyopathies, 189 (1964).

  12. 12.

    , and , Proc. Europ. Soc. Study Drug Toxic., 4, 30 (1965).

  13. 13.

    , , and , Brit. Med. J., ii, 363 (1965).

  14. 14.

    , , and , U.K. Patent Application No. 46740/62, Belgian Patent No. 641,133.

  15. 15.

    , , and , Brit. J. Pharmacol., 25, 577 (1965).

  16. 16.

    , , and , J. Pharmacol., 128, 131 (1960).

  17. 17.

    , and , J. Pharmacol., 133, 202 (1961).

  18. 18.

    , and , Biochem. Pharmacol., 14, 227 (1965).

  19. 19.

    (personal communication).

Download references

Author information

Affiliations

  1. Imperial Chemical Industries, Ltd., Pharmaceuticals Division, Alderley Park, Macclesfield, Cheshire.

    • R. G. SHANKS
    •  & T. M. WOOD
  2. Medical Unit, St. George's Hospital, London, S.W.1.

    • A. C. DORNHORST
    •  & M. L. CLARK

Authors

  1. Search for R. G. SHANKS in:

  2. Search for T. M. WOOD in:

  3. Search for A. C. DORNHORST in:

  4. Search for M. L. CLARK in:

About this article

Publication history

Published

DOI

https://doi.org/10.1038/212088a0

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.